Interleukin-6 (IL-6) -572C→G promoter polymorphism is associated with type 2 diabetes risk in Koreans

Soo Jeong Koh, Yangsoo Jang, Yae Jung Hyun, Ju Yeon Park, Young Duk Song, Kyung Kyun Shin, Jey Sook Chae, Byung Keuk Kim, Jose M. Ordovas, Jong Ho Lee

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: Increased levels of inflammatory markers, such as interleukin-6 (IL-6), are associated with type 2 diabetes (T2DM). We investigated the association of IL-6 gene polymorphisms with T2DM and circulating levels of IL-6 in Koreans. Subjects: A total of 1477 subjects with normal glucose tolerance and 476 T2DM patients were included. Measurements: We examined IL-6 -174G→C, -572C→G, -597G→A and -1363G→T promoter region polymorphisms. The main outcome measures were the odds ratio (OR) on T2DM risk and serum concentrations of IL-6 and high-sensitivity C-reactive protein (hs-CRP). Results: Homozygosity for the rare G allele IL-6 -572C→G was associated with a higher risk of T2DM [OR 1.69 (95%CI 1.11-2.58), P = 0.015]. Serum IL-6 concentrations were associated with the IL-6 -572C→G genotype in control subjects (G/G: 2.33 ± 0.41: C/G: 1.53 ± 0.09: C/C: 1.72 ± 0.08 ng/l, P = 0.023). Also in the control group, subjects homozygous for the rare G allele showed significantly higher concentrations of hs-CRP than C/C and C/G carriers (G/G: 13.6 ± 2.9: C/G: 9.2 ± 0.6: C/C: 7.8 ± 0.4 mg/l, P = 0.003). The C-allele at the IL-6 -174 SNP was very rare (< 0.01) and -597G→A and -1363G→T were monomorphic in this population. Conclusions: Our data demonstrate that the IL-6 -572G/G genotype is associated with higher serum IL-6 and hs-CRP concentrations and with increased risk for T2DM.

Original languageEnglish
Pages (from-to)238-244
Number of pages7
JournalClinical Endocrinology
Volume70
Issue number2
DOIs
Publication statusPublished - 2009 Feb 1

Fingerprint

Type 2 Diabetes Mellitus
Interleukin-6
C-Reactive Protein
Alleles
Serum
Odds Ratio
Genotype
Protein C
Genetic Promoter Regions
Single Nucleotide Polymorphism
Outcome Assessment (Health Care)
Glucose
Control Groups

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Koh, Soo Jeong ; Jang, Yangsoo ; Hyun, Yae Jung ; Park, Ju Yeon ; Song, Young Duk ; Shin, Kyung Kyun ; Chae, Jey Sook ; Kim, Byung Keuk ; Ordovas, Jose M. ; Lee, Jong Ho. / Interleukin-6 (IL-6) -572C→G promoter polymorphism is associated with type 2 diabetes risk in Koreans. In: Clinical Endocrinology. 2009 ; Vol. 70, No. 2. pp. 238-244.
@article{84cf7ccddf724458bc597ac9aa4af3be,
title = "Interleukin-6 (IL-6) -572C→G promoter polymorphism is associated with type 2 diabetes risk in Koreans",
abstract = "Objective: Increased levels of inflammatory markers, such as interleukin-6 (IL-6), are associated with type 2 diabetes (T2DM). We investigated the association of IL-6 gene polymorphisms with T2DM and circulating levels of IL-6 in Koreans. Subjects: A total of 1477 subjects with normal glucose tolerance and 476 T2DM patients were included. Measurements: We examined IL-6 -174G→C, -572C→G, -597G→A and -1363G→T promoter region polymorphisms. The main outcome measures were the odds ratio (OR) on T2DM risk and serum concentrations of IL-6 and high-sensitivity C-reactive protein (hs-CRP). Results: Homozygosity for the rare G allele IL-6 -572C→G was associated with a higher risk of T2DM [OR 1.69 (95{\%}CI 1.11-2.58), P = 0.015]. Serum IL-6 concentrations were associated with the IL-6 -572C→G genotype in control subjects (G/G: 2.33 ± 0.41: C/G: 1.53 ± 0.09: C/C: 1.72 ± 0.08 ng/l, P = 0.023). Also in the control group, subjects homozygous for the rare G allele showed significantly higher concentrations of hs-CRP than C/C and C/G carriers (G/G: 13.6 ± 2.9: C/G: 9.2 ± 0.6: C/C: 7.8 ± 0.4 mg/l, P = 0.003). The C-allele at the IL-6 -174 SNP was very rare (< 0.01) and -597G→A and -1363G→T were monomorphic in this population. Conclusions: Our data demonstrate that the IL-6 -572G/G genotype is associated with higher serum IL-6 and hs-CRP concentrations and with increased risk for T2DM.",
author = "Koh, {Soo Jeong} and Yangsoo Jang and Hyun, {Yae Jung} and Park, {Ju Yeon} and Song, {Young Duk} and Shin, {Kyung Kyun} and Chae, {Jey Sook} and Kim, {Byung Keuk} and Ordovas, {Jose M.} and Lee, {Jong Ho}",
year = "2009",
month = "2",
day = "1",
doi = "10.1111/j.1365-2265.2008.03315.x",
language = "English",
volume = "70",
pages = "238--244",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "2",

}

Interleukin-6 (IL-6) -572C→G promoter polymorphism is associated with type 2 diabetes risk in Koreans. / Koh, Soo Jeong; Jang, Yangsoo; Hyun, Yae Jung; Park, Ju Yeon; Song, Young Duk; Shin, Kyung Kyun; Chae, Jey Sook; Kim, Byung Keuk; Ordovas, Jose M.; Lee, Jong Ho.

In: Clinical Endocrinology, Vol. 70, No. 2, 01.02.2009, p. 238-244.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interleukin-6 (IL-6) -572C→G promoter polymorphism is associated with type 2 diabetes risk in Koreans

AU - Koh, Soo Jeong

AU - Jang, Yangsoo

AU - Hyun, Yae Jung

AU - Park, Ju Yeon

AU - Song, Young Duk

AU - Shin, Kyung Kyun

AU - Chae, Jey Sook

AU - Kim, Byung Keuk

AU - Ordovas, Jose M.

AU - Lee, Jong Ho

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Objective: Increased levels of inflammatory markers, such as interleukin-6 (IL-6), are associated with type 2 diabetes (T2DM). We investigated the association of IL-6 gene polymorphisms with T2DM and circulating levels of IL-6 in Koreans. Subjects: A total of 1477 subjects with normal glucose tolerance and 476 T2DM patients were included. Measurements: We examined IL-6 -174G→C, -572C→G, -597G→A and -1363G→T promoter region polymorphisms. The main outcome measures were the odds ratio (OR) on T2DM risk and serum concentrations of IL-6 and high-sensitivity C-reactive protein (hs-CRP). Results: Homozygosity for the rare G allele IL-6 -572C→G was associated with a higher risk of T2DM [OR 1.69 (95%CI 1.11-2.58), P = 0.015]. Serum IL-6 concentrations were associated with the IL-6 -572C→G genotype in control subjects (G/G: 2.33 ± 0.41: C/G: 1.53 ± 0.09: C/C: 1.72 ± 0.08 ng/l, P = 0.023). Also in the control group, subjects homozygous for the rare G allele showed significantly higher concentrations of hs-CRP than C/C and C/G carriers (G/G: 13.6 ± 2.9: C/G: 9.2 ± 0.6: C/C: 7.8 ± 0.4 mg/l, P = 0.003). The C-allele at the IL-6 -174 SNP was very rare (< 0.01) and -597G→A and -1363G→T were monomorphic in this population. Conclusions: Our data demonstrate that the IL-6 -572G/G genotype is associated with higher serum IL-6 and hs-CRP concentrations and with increased risk for T2DM.

AB - Objective: Increased levels of inflammatory markers, such as interleukin-6 (IL-6), are associated with type 2 diabetes (T2DM). We investigated the association of IL-6 gene polymorphisms with T2DM and circulating levels of IL-6 in Koreans. Subjects: A total of 1477 subjects with normal glucose tolerance and 476 T2DM patients were included. Measurements: We examined IL-6 -174G→C, -572C→G, -597G→A and -1363G→T promoter region polymorphisms. The main outcome measures were the odds ratio (OR) on T2DM risk and serum concentrations of IL-6 and high-sensitivity C-reactive protein (hs-CRP). Results: Homozygosity for the rare G allele IL-6 -572C→G was associated with a higher risk of T2DM [OR 1.69 (95%CI 1.11-2.58), P = 0.015]. Serum IL-6 concentrations were associated with the IL-6 -572C→G genotype in control subjects (G/G: 2.33 ± 0.41: C/G: 1.53 ± 0.09: C/C: 1.72 ± 0.08 ng/l, P = 0.023). Also in the control group, subjects homozygous for the rare G allele showed significantly higher concentrations of hs-CRP than C/C and C/G carriers (G/G: 13.6 ± 2.9: C/G: 9.2 ± 0.6: C/C: 7.8 ± 0.4 mg/l, P = 0.003). The C-allele at the IL-6 -174 SNP was very rare (< 0.01) and -597G→A and -1363G→T were monomorphic in this population. Conclusions: Our data demonstrate that the IL-6 -572G/G genotype is associated with higher serum IL-6 and hs-CRP concentrations and with increased risk for T2DM.

UR - http://www.scopus.com/inward/record.url?scp=58549086336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58549086336&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2008.03315.x

DO - 10.1111/j.1365-2265.2008.03315.x

M3 - Article

C2 - 18573122

AN - SCOPUS:58549086336

VL - 70

SP - 238

EP - 244

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -